Ulisse Biomed Statistics
Total Valuation
Ulisse Biomed has a market cap or net worth of EUR 18.36 million. The enterprise value is 17.19 million.
Market Cap | 18.36M |
Enterprise Value | 17.19M |
Important Dates
The next estimated earnings date is Friday, June 27, 2025.
Earnings Date | Jun 27, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Ulisse Biomed has 24.48 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 24.48M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 23.91 |
PB Ratio | 0.78 |
P/TBV Ratio | 4.35 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.89 |
EV / Sales | 22.39 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -4.83 |
Financial Position
The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.01.
Current Ratio | 1.70 |
Quick Ratio | 1.11 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | -0.09 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.28% and return on invested capital (ROIC) is -13.92%.
Return on Equity (ROE) | -23.28% |
Return on Assets (ROA) | -12.17% |
Return on Invested Capital (ROIC) | -13.92% |
Return on Capital Employed (ROCE) | -23.87% |
Revenue Per Employee | 95,991 |
Profits Per Employee | -742,477 |
Employee Count | 10 |
Asset Turnover | 0.03 |
Inventory Turnover | 0.74 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.94% in the last 52 weeks. The beta is 0.70, so Ulisse Biomed's price volatility has been lower than the market average.
Beta (5Y) | 0.70 |
52-Week Price Change | -40.94% |
50-Day Moving Average | 0.78 |
200-Day Moving Average | 0.89 |
Relative Strength Index (RSI) | 46.66 |
Average Volume (20 Days) | 18,950 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ulisse Biomed had revenue of EUR 767,929 and -5.94 million in losses.
Revenue | 767,929 |
Gross Profit | -622,385 |
Operating Income | -5.77M |
Pretax Income | -5.94M |
Net Income | -5.94M |
EBITDA | -2.85M |
EBIT | -5.77M |
Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 1.50 million in cash and 333,889 in debt, giving a net cash position of 1.17 million or 0.05 per share.
Cash & Cash Equivalents | 1.50M |
Total Debt | 333,889 |
Net Cash | 1.17M |
Net Cash Per Share | 0.05 |
Equity (Book Value) | 23.67M |
Book Value Per Share | n/a |
Working Capital | 2.14M |
Cash Flow
In the last 12 months, operating cash flow was -3.56 million and capital expenditures -2,168, giving a free cash flow of -3.56 million.
Operating Cash Flow | -3.56M |
Capital Expenditures | -2,168 |
Free Cash Flow | -3.56M |
FCF Per Share | -0.15 |
Margins
Gross Margin | -81.05% |
Operating Margin | -751.77% |
Pretax Margin | -773.49% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Ulisse Biomed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -32.35% |
FCF Yield | -19.40% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Ulisse Biomed has an Altman Z-Score of 2.81. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.81 |
Piotroski F-Score | n/a |